The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.
JOURNAL OF CLINICAL ONCOLOGY（2023）
关键词
neoadjuvant ipilimumab,melanoma,adjuvant therapy,response-directed,long-term,three-year,opacin-neo
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要